# Neuroscience & Biomarker Solutions for CNS Clinical Trials. IXICO is a neuroscience company delivering AI-powered neuroimaging and biomarker analysis for CNS clinical trials. Trusted by global pharma and biotech to accelerate drug development. # Precision In Neuroscience ## Advancing medicine through the provision of precision imaging biomarker insights for the discovery, development and delivery of novel treatments in neurological disease [ IXI™ Platform ](/platform/) [ IXICO Services ](/services/) ## A global leader in neuroimaging and biomarker analytics [ About IXICO ](/company/) IXI™ is IXICO’s proprietary, AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research. The Platform, combined with IXICO's expert clinical trial operations, helps accelerate decision-making in clinical research and maximise the potential of drug development programmes. ## Join IXICO's Networking Breakfast at CTAD 2026: The Future of Amyloid Assessment Start your day with breakfast, networking and expert perspectives on the future of amyloid assessment. Featuring lightning talks from Mike Weiner, UCSF; Tobias Bittner, Roche; and Robin Wolz, IXICO, covering screening, multimodal assessment and the opportunities for AI. Wednesday 18 Nov \| 07.00 - 08.20 \| Salon A [ Register now to secure your spot! ](https://fywsr.share-eu1.hsforms.com/25nzsnDBxQRGsJ-mJ8cBwUg) ## Neuroscience Expertise IXICO has built a global reputation as a leading end-to-end Imaging Contract Research Organisation (iCRO), expertly managing and analysing neurological clinical trials. The Company is a key part of the global neurological disease research community, with a 20-year proven track record in the biopharmaceutical industry, working with leading pharma companies, innovative biotechs, scientific consortia, and non-profit organisations. [ Therapeutic Areas ](/therapeutic-areas/) ## Differentiated Technology [ IXI™ Platform ](/platform/) The IXI™ Platform is tailor-made for neurological diseases, reliably managing global clinical trial data, precisely reading radiological scans, and measuring key imaging biomarkers linked to the identification, progression, and treatment of conditions such as Alzheimer’s, Huntington’s, and Parkinson’s disease. ## Explore news and resources from IXICO [ View here ](/news-and-resources/) [ View here ](/news-and-resources/) [ ![IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/assets/blog-images/AD-contract-advancements__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) news [#### IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) [ ![IXICO announces 28% expected revenue growth for FY26](/assets/blog-images/Trading-update-FY26__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) news [#### IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) [ ![Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](/assets/blog-images/AD-Webinar-2026-1__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/webinars/where-vascular-disease-and-alzheimers-meet-shared-pathways-to-cognitive-decline/) webinars [#### Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](/news-and-resources/webinars/where-vascular-disease-and-alzheimers-meet-shared-pathways-to-cognitive-decline/) [ ![Neuromelanin-Sensitive MRI of the Substantia Nigra: Comparing TSE and MT-GRE Contrast](/assets/blog-images/ESMRMB-2026__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/publications/contrast-ratio-assessment-of-the-substantia-nigra-in-neuromelanin-sensitive-mri/) publications [#### Neuromelanin-Sensitive MRI of the Substantia Nigra: Comparing TSE and MT-GRE Contrast](/news-and-resources/publications/contrast-ratio-assessment-of-the-substantia-nigra-in-neuromelanin-sensitive-mri/) [ ![IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/assets/blog-images/advancements-in-neuroimaging-for-Parkinsons-disease__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) news [#### IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) [ ![Beyond Diagnosis: 8 MRI and PET Biomarkers Shaping Alzheimer's Clinical Trials](/assets/blog-images/Alzheimers-biomarkers__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/blog/pet-mri-biomarkers-alzheimers-clinical-trials/) blog [#### Beyond Diagnosis: 8 MRI and PET Biomarkers Shaping Alzheimer's Clinical Trials](/news-and-resources/blog/pet-mri-biomarkers-alzheimers-clinical-trials/) [ ![White matter hyperintensities: A precision neurology tool for Alzheimer’s patient stratification and improved trial sensitivity? ](/assets/blog-images/WMH-blog-title__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJqcGciLCJ3ZWJwIl0.webp) ](/news-and-resources/blog/white-matter-hyperintensities-a-precision-neurology-tool-for-alzheimers-patient-stratification-and-improved-trial-sensitivity/) blog [#### White matter hyperintensities: A precision neurology tool for Alzheimer’s patient stratification and improved trial sensitivity? ](/news-and-resources/blog/white-matter-hyperintensities-a-precision-neurology-tool-for-alzheimers-patient-stratification-and-improved-trial-sensitivity/) [ ![IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER’S AND PARKINSON’S DISEASE](/assets/blog-images/IXICO-EXPANDS-RESEARCH-COLLABORATIONS-IN-ALZHEIMERS-AND-PARKINSONS-DISEASE-1__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJqcGciLCJ3ZWJwIl0.webp) ](/news-and-resources/news/ixico-expands-research-collaborations-in-alzheimers-and-parkinsons-disease/) news [#### IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER’S AND PARKINSON’S DISEASE](/news-and-resources/news/ixico-expands-research-collaborations-in-alzheimers-and-parkinsons-disease/) [ ![Neuromelanin MRI: An Early, Longitudinal Biomarker for Parkinson’s Disease](/assets/blog-images/Neuromelanin-Blog__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJqcGciLCJ3ZWJwIl0.webp) ](/news-and-resources/blog/neuromelanin-mri-an-early-longitudinal-biomarker-for-parkinsons-disease/) blog [#### Neuromelanin MRI: An Early, Longitudinal Biomarker for Parkinson’s Disease](/news-and-resources/blog/neuromelanin-mri-an-early-longitudinal-biomarker-for-parkinsons-disease/) [ ![IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/assets/blog-images/AD-contract-advancements__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) news [#### IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) [ ![IXICO announces 28% expected revenue growth for FY26](/assets/blog-images/Trading-update-FY26__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) news [#### IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) [ ![Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](/assets/blog-images/AD-Webinar-2026-1__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/webinars/where-vascular-disease-and-alzheimers-meet-shared-pathways-to-cognitive-decline/) webinars [#### Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](/news-and-resources/webinars/where-vascular-disease-and-alzheimers-meet-shared-pathways-to-cognitive-decline/) [ ![Neuromelanin-Sensitive MRI of the Substantia Nigra: Comparing TSE and MT-GRE Contrast](/assets/blog-images/ESMRMB-2026__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/publications/contrast-ratio-assessment-of-the-substantia-nigra-in-neuromelanin-sensitive-mri/) publications [#### Neuromelanin-Sensitive MRI of the Substantia Nigra: Comparing TSE and MT-GRE Contrast](/news-and-resources/publications/contrast-ratio-assessment-of-the-substantia-nigra-in-neuromelanin-sensitive-mri/) [ ![IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/assets/blog-images/advancements-in-neuroimaging-for-Parkinsons-disease__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) news [#### IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) [ ![Beyond Diagnosis: 8 MRI and PET Biomarkers Shaping Alzheimer's Clinical Trials](/assets/blog-images/Alzheimers-biomarkers__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) ](/news-and-resources/blog/pet-mri-biomarkers-alzheimers-clinical-trials/) blog [#### Beyond Diagnosis: 8 MRI and PET Biomarkers Shaping Alzheimer's Clinical Trials](/news-and-resources/blog/pet-mri-biomarkers-alzheimers-clinical-trials/) [ ![White matter hyperintensities: A precision neurology tool for Alzheimer’s patient stratification and improved trial sensitivity? ](/assets/blog-images/WMH-blog-title__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJqcGciLCJ3ZWJwIl0.webp) ](/news-and-resources/blog/white-matter-hyperintensities-a-precision-neurology-tool-for-alzheimers-patient-stratification-and-improved-trial-sensitivity/) blog [#### White matter hyperintensities: A precision neurology tool for Alzheimer’s patient stratification and improved trial sensitivity? ](/news-and-resources/blog/white-matter-hyperintensities-a-precision-neurology-tool-for-alzheimers-patient-stratification-and-improved-trial-sensitivity/) [ ![IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER’S AND PARKINSON’S DISEASE](/assets/blog-images/IXICO-EXPANDS-RESEARCH-COLLABORATIONS-IN-ALZHEIMERS-AND-PARKINSONS-DISEASE-1__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJqcGciLCJ3ZWJwIl0.webp) ](/news-and-resources/news/ixico-expands-research-collaborations-in-alzheimers-and-parkinsons-disease/) news [#### IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER’S AND PARKINSON’S DISEASE](/news-and-resources/news/ixico-expands-research-collaborations-in-alzheimers-and-parkinsons-disease/) [ ![Neuromelanin MRI: An Early, Longitudinal Biomarker for Parkinson’s Disease](/assets/blog-images/Neuromelanin-Blog__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJqcGciLCJ3ZWJwIl0.webp) ](/news-and-resources/blog/neuromelanin-mri-an-early-longitudinal-biomarker-for-parkinsons-disease/) blog [#### Neuromelanin MRI: An Early, Longitudinal Biomarker for Parkinson’s Disease](/news-and-resources/blog/neuromelanin-mri-an-early-longitudinal-biomarker-for-parkinsons-disease/)